Meamo's website sells unapproved, misbranded injectable botulinum toxin drugs to U.S. consumers, FDA says.
What happened
FDA reviewed www.meamoshop.com and found it offers unapproved and misbranded injectable botulinum toxin drug products for sale to U.S. consumers. FDA cited examples marketed as “X4 Wondertox 100U Set” and “Wondertox,” including a website claim for “Treatment of benign essential blepharspasm in adult patients.” FDA said there are no approved applications for these products.
What FDA found
The website offers new drugs without FDA approval.
FD&C Act sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drug labeling lacks adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]Offering these drugs for sale causes misbranded drugs to enter interstate commerce.
FD&C Act section 301(a) [21 U.S.C. § 331(a)]The drugs are not exempt from adequate-directions requirements because they are not approved in the U.S.
21 CFR 201.115(a)
What FDA wants
FDA requests that www.meamoshop.com stop offering unapproved and misbranded drugs for sale to U.S. consumers. The company must notify FDA in writing within 15 working days describing corrective steps, or explain the delay and completion time.
Who should pay attention
- U.S. consumers buying injectable drugs online
- online retailers and distributors of botulinum toxin products
- importers and suppliers of unapproved drug products
This is a summary. Read the original letter on fda.gov.